(Yicai Global) Jan. 31 -- Chinese drug company Zhejiang Tianyu Pharmaceutical Co. has received approvals from local regulators to commence sales of its active pharmaceutical ingredient for curing hypertension on the Japanese market.

The Taizhou-based firm has received a notice from Japan's Pharmaceuticals and Medical Devices Agency stating the API, named Irbesartan, has passed compliance checks, the company said in a press briefing yesterday.

Tianyu Pharma expects irbesartan's introduction in the country to have a positive effect on its financial results in the future. The API is used primarily to treat hypertension as well as type-II diabetes and nephropathy complicated by hypertension.

Founded in 1993, Zhejiang Tianyu Pharmaceutical covers stages from research and development to manufacture and sale of pharmaceutical intermediates and APIs mainly in China, for use in drugs used for cardiovascular, anti-diabetic, anti-atherosclerosis, anticoagulant, and anti-asthmatic issues.